Platelet Activation, Sickle Cell Disease, Thromboinflammation
Conditions
Keywords
Sickle cell disease, vaso-occlusive crisis, platelets, thrombo-inflammation
Brief summary
Sickle cell disease (SCD) is an autosomal recessive genetic disorder linked to a single mutation on beta-globin chains. This leads to red blood cell deformation and chronic hemolysis which can result in vaso-occlusive events, anemia and vasculopathy. Pathophysiology is incompletely understood, and beyond red blood cell's abnormalities this involves hemostasis and innate immunity. The aim of our study is to describe the mechanisms of thrombo-inflammation during the vaso-occlusive crisis (VOC) in adults with sickle cell disease.
Detailed description
Pathophysiology of sickle cell disease is incompletely understood. The typical change of red blood cells into sickle cells lead to post-capillary stream abnormalities. This phenomenon is responsible of ischemia-reperfusion injuries. Chronic hemolysis is the second part of the pathophysiology. The consequences are vasoconstriction, endothelial lesions, chronic inflammation, hemostasis and platelets activation. Thrombo-inflammation concept was proposed by Tanguay to describe the interactions between hemostasis, platelets and innate immune cells (neutrophils polynuclear) during thrombotic process. Since this time, this concept was largely described in many clinical situations such as septicemia, COVID-19, coronaropathy, auto-immune diseases and sickle cell disease. In this project, we will study platelets activation and thrombo-inflammation markers in the beginning of a vaso-occlusive crisis, during the crisis and two months after the crisis. Blood samples will be collected during a routine care sample. Biological markers studied will be: * Soluble and surface markers of platelet activation; platelet-leukocytes aggregates * Plasmatic eicosanoids produced by platelets (TXB2) and immune cells * In vitro platelets reactivity; dynamic thrombus formation in normal and pathologic arterial blood stream * Platelet's inflammasome
Interventions
BIOLOGICALBlood sampling
the blood sample will be taken during a planned blood sampling
Sponsors
University Hospital, Toulouse
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patient with sickle cell disease diagnosis, hospitalized in emergency department and/or internal medicine department * Patient older than 18 years * Written consent to participate to the study * Patient with health insurance * Patient able to receive information about the study
Exclusion criteria
* Age \< 18 years * Non consent to participate to the study * Women in pregnancy or breastfeeding * Treatment with aspirin or non steroidal anti inflammatory drug * Protected patient * Patient already involved in a study requiring collection of additional biological samples
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate mechanisms of platelet activation in the thrombo-inflammation process during a vaso-occlusive crisis. | First 48h of hospitalization | by flow cytometry analysis |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORPierre Cougoul, MD
University Hospital, Toulouse
Outcome results
None listed